T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL

BACKGROUND: Clozapine is the most effective anti-psychotic for treatment refractory schizophrenia, but causes significant metabolic disturbances including obesity and type 2 diabetes. The metabolic adverse reactions may be mediated in part by clozapine induced dysregulation of Glucagon-like-peptide-...

Descripción completa

Detalles Bibliográficos
Autores principales: Siskind, Dan, Russell, Anthony, Gamble, Clare, Winckel, Karl, Hollingworth, Sam, Kisely, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888874/
http://dx.doi.org/10.1093/schbul/sby016.436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888874/
http://dx.doi.org/10.1093/schbul/sby016.436

Ejemplares similares